ClinicalTrials.gg
RecruitingNCT06283186Updated Feb 27, 2025

Comparative Exercise-Induced Hypoalgesia in Upper and Lower Limbs: A Randomized Controlled Trial in Healthy Individuals

A Phase 1 interventional study of Aerobic exercise and Aerobic exercise in Healthy Subjects, sponsored by Centro Universitario La Salle. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Centro Universitario La Salle · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This randomized controlled trial with healthy subjects aims to compare exercise-induced hypoalgesia among three groups: one utilizing a lower limb cycle ergometer, another using an upper limb cycle ergometer, and a control group. The exercise protocol involves 30 minutes of aerobic activity at 70-80% of the heart rate reserve. Exercise-induced hypoalgesia will be assessed by measuring pressure pain thresholds in the thigh and elbow. Additionally, a secondary objective is to compare the lower limb and upper limb cycle ergometer groups in terms of their effects on pressure pain thresholds in the thigh and elbow. Thus, the study anticipates observing differences in local and distal hypoalgesia based on the trained region.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Local Hypoalgesia
  • Distal Hypoalgesia
  • Aerobic Exercise
  • Pressure Pain Thresholds
03

In context

Lead sponsor

Centro Universitario La Salle is the lead sponsor of 25 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asymptomatic subjects aged between 18 and 64 years.

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular, respiratory, metabolic, neurological, or osteomuscular signs or pathologies.
  • History of epilepsy.
  • Pregnant
  • Pharmacological treatment.
  • Participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 12 weeks.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Lower limb cycle ergometer

    The participants in the lower limb cycle ergometer group will undergo a 30-minute aerobic exercise intervention comprising a 5-minute warm-up, 20 minutes of training at 70-80% of the heart rate reserve, and a 5-minute cool-down.

    Other: Aerobic exercise

  • Experimental
    Upper limb cycle ergometer

    The participants in the upper limb cycle ergometer group will undergo a 30-minute aerobic exercise intervention comprising a 5-minute warm-up, 20 minutes of training at 70-80% of the heart rate reserve, and a 5-minute cool-down.

    Other: Aerobic exercise

  • No intervention
    Control

    Participants in the control group will remain seated for the entire 30-minute duration of the experiment without receiving any form of distraction.

Interventions

  • OtherAerobic exercise

    Aerobic exercise with lower limb cycle ergometer

  • OtherAerobic exercise

    Aerobic exercise with upper limb cycle ergometer

06

What researchers measure

Primary outcomes

  1. Pressure pain threshold (PPT) on dominant quadriceps and dominant lateral epicondyle

    PPT is tested on the muscle belly of the quadriceps on the dominant side, 10 centimeters cranial to the superior pole of the patella, and on the muscle belly of the epicondyle muscles on the dominant side, 5 centimeters caudal to the epicondyle. The region to be pressed is marked with a pen. The patient is instructed to report the first appearance of the sensation of "discomfort". An ascending ramp of 0.5 kg/cm/s is applied, at the rhythm of a metronome. The measurement is started on the quadriceps and alternated with the epicondyle until 3 measurements of each region are obtained. Each measurement in the same region is obtained after 30 seconds of rest. This protocol has demonstrated high inter-observer reliability measuring healthy subjects (ICC = 0.91).

    Time frame: Three measurementes: before, immediately after intervention, and 30 minutes after intervention

Secondary outcomes

  1. International Physical Activity Questionnaire (IPAQ)

    7-item questionnaire on the level of physical activity at different intensities (high, moderate, and low) and hours sitting. A higher score means higher weekly physical activity.

    Time frame: Before intervention (up 5 minutes)

  2. Fatigue Assessment Scale (FAS)

    10-item questionnaire that allows for the evaluation of the participant's current level of fatigue. A higher score means higher fatigue.

    Time frame: Before intervention (up 5 minutes)

  3. Heart rate

    Heart rate will be measured during the procedure by a Polar H10 sensor and a Polar Ignate WR 30M watch.

    Time frame: During intervention (up 30 minutes)

  4. Rate of perceived exertion (RPE)

    RPE Borg CR-10 is used to measure how hard your body works during physical activity. It runs from 0 - 10, using numbers to rate how much effort an activity takes.

    Time frame: Immediately after intervention (up 10 seconds)

  5. Physical Activity Readiness Questionnaire (PAR-Q)

    7-item questionnaire that assesses an individual's readiness to engage in physical activity based on whether any known contraindications have been ruled out by the participant. If all the questions are negative, the participant can safely engage in a physical activity.

    Time frame: Before intervention (up 5 minutes)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jul 2025, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 28, 2024
StartActual
Apr 23, 2024
Primary completionEst.
Jul 31, 2025
CompletionEst.
Jul 31, 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06283186
Lead sponsor
Centro Universitario La Salle
Responsible party
Álvaro Reina Varona (Principal Investigator, Centro Universitario La Salle) — Principal investigator
First posted
Feb 28, 2024
Start date
Apr 23, 2024
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Feb 27, 2025

Study contacts

Álvaro Reina-Varona, MSc
Contact
alvaro.reina@lasallecampus.es
0034+649001863

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion